Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Even as the Ebola outbreak caused by the rare Bundibugyo Ebola virus continues to spread, a new case study has revealed a striking finding: the lesser-known virus can remain at very high levels in a patient’s throat.

Ebola viruses are primarily known to attack the vascular system, damaging blood vessel integrity and disrupting the body’s ability to clot. This can lead to severe fluid loss, organ failure and, in some cases, internal or external bleeding.

However, a case study of a 39-year-old American healthcare worker infected with Bundibugyo Ebola virus in the Democratic Republic of the Congo (DRC) found that his throat carried more than 10 times as much viral RNA as his blood.

The patient was later medically evacuated to Germany, where he received experimental treatment at a high-level isolation unit in Berlin.

Throat Carried 10 Times More Virus

On day five of illness, testing showed:

• Throat: About 90 million viral RNA copies/mL
• Blood plasma: About 7 million copies/mL
• Difference: The throat had more than 10 times the viral RNA found in blood.

The case was published in Nature Medicine by researchers from Charité – Universitätsmedizin Berlin, with collaborators including the CDC, US Department of State, Robert Koch Institute, Emory University and Congo’s Institut National de Recherche Biomédicale.

How Was He Exposed?

The healthcare worker had performed an ultrasound nine days before symptoms began.

Eight days before symptoms, he performed two surgeries using standard personal protective equipment and reported no specific high-risk exposure.

He voluntarily isolated himself when symptoms began. His early symptoms included:

• Severe muscle pain and malaise
• 38.9°C fever despite acetaminophen
• Positive pan-Ebola PCR on plasma by day two

By day three, he developed abdominal pain, vomiting, confusion and orthostatic symptoms.

Experimental Treatment Was Given

Bundibugyo Ebola virus has so far caused three recorded outbreaks, but there are currently no licensed vaccines or specific treatments for the disease.

The patient had received a dose of rVSV-ZEBOV 41 months earlier, but that vaccine targets the Zaire species.

He received the investigational antibody cocktail MBP134 on day four, along with a 200 mg loading dose of remdesivir off-label.

He reached Berlin on day five with thrombocytopenia, lymphopenia and elevated liver enzymes.

Viral RNA Cleared From Most Samples

By day 13, viral RNA was below detection levels in his:

• Plasma
• Throat
• Urine
• Stool

However, the virus was still detected in semen on day 20 but was gone by day 25. Three laboratories failed to culture live virus from throat, plasma or semen samples, the report said.

The researchers cautioned that this cannot be directly attributed to MBP134 because pre-treatment culture data were unavailable. The patient was discharged 22 days after symptom onset.

His Immune System Also Responded

Researchers found rising antibodies against the virus between days five and six, along with virus-specific IgM and IgA, suggesting that his own immune system mounted a response despite receiving monoclonal antibodies.

However, the researchers stressed that the case does not prove MBP134, remdesivir or their combination works. Larger studies are needed.

Congo Ebola Outbreak

Congo declared the outbreak in Ituri Province on May 15, 2026, followed by a WHO public health emergency of international concern two days later.

As of August 22, the ECDC reported:

• 5,514 confirmed cases
• 2,642 deaths
• 4,607 cases and 2,065 deaths in Ituri

The Cyclospora outbreak ongoing in the US since May this year has reached 17,180 cases, compared with 1,180 cases through August last year, according to the latest figures released by the Centers for Disease Control and Prevention (CDC).

The cases, reported across 48 states plus the District of Columbia, include two deaths, while 922 people have been hospitalized.

In addition, the CDC is investigating 11,844 additional cases that have not yet been laboratory-confirmed. The federal agency added that the true number of people sick with cyclosporiasis is likely higher because some people recover without medical care and are not tested for Cyclospora.

“Recent illnesses may not yet be reported due to the time it takes to identify and report Cyclospora cases. It can take about six weeks from the start of symptoms to when CDC receives the case information,” the CDC said.

Cyclospora Cases Expected To Dwindle

Historically, the cyclosporiasis season in the United States runs from May 1 through August 31, so cases should dwindle as summer ends, the CDC said.

The largest outbreak this summer was reported in Michigan. Last week, Michigan noted a 3% increase in cases, bringing the state's total to 14,277 cases.

Outbreak Linked To Iceberg Lettuce

The outbreak has been linked to iceberg lettuce, particularly lettuce produced by Taylor Farms de Mexico. The lettuce was sold at stores and at Taco Bell restaurants across the US before it was recalled.

Cyclosporiasis is caused by a parasite that spreads through food and water contaminated with infected human feces.

The Food and Drug Administration, which oversees food safety, has said it is “confident that all recalled iceberg lettuce related to this specific Cyclospora outbreak is off the market.”

While an average American reportedly eats about 18.3 pounds of lettuce each year, consumers purchased about 7.6 million fewer pounds of lettuce during the four weeks ending July 18 compared with the same period last year, according to The Wall Street Journal.

Is It Safe To Eat Lettuce Right Now?

Food safety experts noted that people can eat lettuce now, but should choose their greens wisely.

“Consumers should make informed choices rather than avoiding leafy greens altogether,” said Darin Detwiler, a professor at Northeastern University, Food & Wine reported.

Because the recalls so far are tied to specific products from one producer and have not expanded to include other lettuce producers, other products are likely OK, Detwiler said.

“Consumers should follow FDA and CDC recall information rather than assuming every leafy green product is unsafe,” he said.

Wade Syers, an extension specialist for food safety at Michigan State University Extension, said the ongoing Cyclospora investigation “does not mean all lettuce or all leafy greens are unsafe.”

How To Prevent Cyclospora Infection

To reduce the risk of infection, the CDC recommends:

• Wash your hands before handling food.
• Wash fresh produce under running water before eating, preparing or cooking it.
• Cook food to at least 158°F (70°C) to kill Cyclospora.
• Follow CDC and FDA recall notices and avoid recalled products.
• Avoid bagged salad mixes.

Food safety has become a serious concern in the US in recent months, with a large number of products recalled over contamination, bacterial infections, and other health risks.

The latest recalls involve rice over potential foreign material contamination and mini doughnuts over undeclared milk that may trigger allergic reactions.

Mini Donuts Recalled Over Undeclared Milk

Packages of mini donuts sold nationwide are being recalled after a consumer reported an allergic reaction linked to the product, USA Today reported.

According to the US Food and Drug Administration (FDA), Better Bakehouse Snack Company is recalling certain lots of Donutful Chocolate Dipped Vanilla Cake Donuts because they may contain undeclared milk.

People with a milk allergy or severe sensitivity to milk could face a serious or life-threatening allergic reaction if they consume the affected product, the FDA said.

The food regulator noted that the consumer who suffered the allergic reaction has fully recovered. The manufacturer has identified the cause of the mislabeling and taken corrective measures.

Also read: From Dog Food To Fruit Bars: Over 10 Products Recalled In US Over Contamination

Which Doughnuts Are Being Recalled?

The recalled doughnuts are limited to a specific lot manufactured and distributed in March 2026. The product was shipped to retailers nationwide and sold through Amazon.

Consumers should check the following details to determine whether they have the recalled product:

• Product: Donutful Chocolate Dipped Vanilla Cake Donuts, 10 Mini Donuts
• Package: 7.05-ounce carton containing five 1.41-ounce (40g) pouches
• UPC: 3 50041 39210 3
• Best If Used By: September 15, 2026
• Lot Code: 26078

The FDA advises consumers to dispose of the affected product and obtain a refund from the point of purchase with a receipt, or return the product for a refund.

54,648 Pounds of Rice Recalled Over Foreign Material

An FDA update on August 25 provides more details about an April 2026 rice recall involving Lundberg Family Farms.

The company's Jasmine white rice was recalled because of potential contamination with foreign materials.

According to the FDA, 27,324 packages of 32-ounce rice were recalled, totaling 54,648 pounds. Lundberg-branded rice was also part of the recall initiated by the FDA in April this year.

The recalled rice was distributed in:

• California
• Connecticut
• Florida
• Illinois
• North Carolina
• New Hampshire
• New York
• Pennsylvania
• Tennessee
• Vermont
• Washington
• Wisconsin

Consumers can identify the affected products using these details:

• UPC: 073416040281
• Lot/Best Before: 260201MA, 01FEB2027; 260202MA, 02FEB2027

The expiration dates are February 1 and February 2, 2027. Consumers who were unaware of the earlier recall announcements may still have the affected product at home.

What Is the Risk From the Recalled Rice?

The recall follows the FDA's May 7 Class II classification.

According to the FDA, a Class II recall involves a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the likelihood of serious adverse health consequences is remote.